{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-083928","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2024-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.617126+00:00","generated_at":"2026-05-31T20:33:44.902392+00:00","sec_items":["1.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Genentech terminates migoprotafib collaboration; Relay loses future milestones","bullets":["Genentech terminated without cause; effective 180 days after July 11, 2024.","Relay had received $121.8M total ($75M upfront + $45M milestones + R&D costs).","No further milestone or royalty payments due after termination date.","Relay regains full rights to migoprotafib (SHP2 inhibitor) and all associated data.","Termination removes expected future payments; drug development status uncertain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-083928","json":"https://secwatch.observer/filing/0000950170-24-083928.json","markdown":"https://secwatch.observer/filing/0000950170-24-083928.md","text":"https://secwatch.observer/filing/0000950170-24-083928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024083928/0000950170-24-083928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024083928/rlay-20240711.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:33:44.902392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}